Abstract

This study seeks to elucidate the efficacy of oxaliplatin, fluorouracil and calcium folinate combined with hepatic arterial infusion chemotherapy, in patients with advanced primary liver cancer. In this study, 156 advanced primary liver cancer individuals who were treated in our hospital between July 2018 and July 2021 were selected among which 70 patients who received folinic acid/calcium folinate, fluorouracil and oxaliplatin regimen via conventional intravenous infusion were assigned as control group and 86 patients who received hepatic arterial infusion chemotherapy using the folinic acid/calcium folinate, fluorouracil and oxaliplatin regimen were included in the research group. The two groups were compared with respect to their curative effects, complication rate (nausea and vomiting, fatigue, fever, abnormal liver function and thrombocytopenia) and improvement of health status using Karnofsky performance scores. Similarly serum indices such as vascular endothelial growth factor, alpha-fetoprotein, cancer antigen 19-9 and 1 y overall survival were also evaluated. Significantly higher overall effectiveness, better improvement of health status (high Karnofsky performance scores) and fewer complications were found in the research group when compared with the control group; the post-treatment vascular endothelial growth factor, alphafetoprotein, cancer antigen 19-9 of the research group reduced statistically and were lower compared with the control group. Notably higher 1 y overall survival was determined in the research group. Therefore, hepatic arterial infusion chemotherapy using the folinic acid/calcium folinate, fluorouracil and oxaliplatin regimen is beneficial to improve the clinical outcomes of advanced primary liver cancer patients with a good preventive effect on the occurrence of complications, which can not only significantly improve patients’ health status, inhibit vascular endothelial growth factor, alpha-fetoprotein, cancer antigen 19-9 levels, but also significantly increase the 1 y overall survival of patients.